SK Bioscience Co, the biotech arm of South Korea’s SK Group, inaugurated its new Global Research & Process Development (R&PD) Centre in Songdo, Incheon. This $255.7 million facility, also serving as the company’s headquarters, focuses on vaccine research. It is the largest facility in South Korea solely dedicated to vaccine development.
The research center aims to streamline the vaccine development process, covering everything from early-stage research to technical validation under one roof. This consolidation is expected to enhance both the speed and quality of SK Bioscience’s vaccine development efforts.
Ahn Jae-young, the CEO of SK Bioscience, emphasized the significance of the move to the Songdo Global R&PD Centre. He highlighted how this step aligns with the company’s long-term growth strategy by providing essential infrastructure for its operations.
SK Bioscience Co reported a net profit of $14.8 million in the third quarter of November 2025, a significant turnaround from the previous year’s loss. Despite an operating loss for the July-September period, the company saw a 144.6% increase in revenue, reaching 150.8 billion won.
President Lee Jae Myung of SK Bioscience engaged in discussions with Bill Gates, the chair of the Gates Foundation, exploring avenues for collaboration in global health initiatives. Gates commended South Korea’s potential contributions to global health through innovative vaccines, diagnostic tools, and other efforts. He also highlighted the achievements of organizations like the Gavi vaccine alliance and the Global Fund in combating diseases like HIV, malaria, and tuberculosis, expressing optimism about South Korea’s role in such initiatives.
